Form 4: Arcellx CFO Gilson Reports Future RSU Vesting & Stock Acquisitions

Arcellx's Chief Financial Officer, Michelle Gilson, filed a Form 4 detailing future acquisitions of common stock through the vesting of Restricted Stock Units under a Rule 10b5-1 plan.

Summary

• Michelle Gilson, Arcellx's Chief Financial Officer, reported future transactions involving the company's common stock and Restricted Stock Units (RSUs).
• The transactions are scheduled to occur in January 2026 and are part of a pre-arranged Rule 10b5-1 trading plan.
• On January 2, 2026, Gilson is set to acquire 20,496 shares of common stock from the vesting of RSUs granted on January 2, 2024.
• On January 3, 2026, Gilson is set to acquire 15,340 shares of common stock from the vesting of RSUs granted on January 3, 2023.
• On January 6, 2026, Gilson is set to acquire 20,530 shares of common stock from the vesting of RSUs granted on January 6, 2025.
• A new grant of 88,542 Restricted Stock Units (RSUs) is reported on January 2, 2026, which will vest 1/4th annually over four years from that date.
• Following these transactions, Gilson's direct beneficial ownership of common stock will increase to 64,832 shares.
• Gilson will also beneficially own 88,542 new RSUs and 61,590 RSUs from a January 6, 2025 grant.

Sentiment

Score: 7

Explanation: The filing is a routine Form 4 reporting scheduled executive compensation events (RSU vesting and grants) under a Rule 10b5-1 plan. It indicates continued alignment of executive interests with shareholders and retention of key management, which is generally positive, but does not contain new material operational or financial news.

Positives

• The reporting of transactions under a Rule 10b5-1 plan indicates pre-planned, non-discretionary transactions, which can reduce concerns about opportunistic insider trading.
• The acquisition of common stock through RSU vesting demonstrates continued equity ownership by a key executive, aligning interests with shareholders.
• A new grant of 88,542 RSUs to the CFO on January 2, 2026, indicates continued long-term incentive compensation and retention of key management.

Risks

• The value of the acquired common stock and the future vesting RSUs is subject to the market price fluctuations of Arcellx, Inc. common stock.
• Vesting of RSUs is contingent upon Michelle Gilson continuing to be a Service Provider (employee) through each applicable vesting date.

Future Outlook

The filing details future equity transactions for the Chief Financial Officer, Michelle Gilson, scheduled for January 2026, indicating continued long-term incentive alignment and retention of key management through equity compensation plans.

Industry Context

This Form 4 filing reflects standard executive compensation practices within the biotechnology or pharmaceutical industry, where Restricted Stock Units (RSUs) are commonly used to align executive interests with long-term shareholder value and to retain key talent. The use of a Rule 10b5-1 plan is also a common practice to manage insider trading compliance.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a significant component of executive compensation is a common practice across the biotechnology and broader technology sectors, comparable to companies like Moderna (MRNA) or Biogen (BIIB) which frequently grant RSUs to executives.
• The vesting schedules (3-4 years) are typical for long-term incentive plans, similar to those observed at peer companies, designed to encourage long-term commitment and performance.
• The establishment of a Rule 10b5-1 plan for these transactions is standard corporate governance practice, providing an affirmative defense against insider trading allegations by pre-scheduling trades.

Corporate Governance

Stakeholder Impact

• Shareholders: Continued alignment of executive interests with shareholder value through equity ownership.
• Employees: Reflects the company's ongoing use of equity incentive plans for key personnel.

Next Steps

• Future vesting events for the 88,542 RSUs granted on January 2, 2026, will occur annually over four years.
• Future vesting events for the 61,590 remaining RSUs from the January 6, 2025 grant will occur annually over four years.

Key Dates

Recommendation

This Form 4 filing reports routine executive compensation events, specifically the vesting of Restricted Stock Units and a new RSU grant, all under a pre-arranged Rule 10b5-1 plan. Such filings are standard and do not typically provide new material information that would warrant a change in investment recommendation. The transactions reflect ongoing executive retention and alignment with shareholder interests, which are generally neutral to slightly positive factors, but do not indicate a fundamental shift in the company's prospects. Therefore, a 'hold' recommendation is appropriate as this filing does not present new catalysts for buying or selling.

Keywords

Arcellx, ACLX, Form 4, Insider Trading, Restricted Stock Units, RSU, Executive Compensation, Michelle Gilson, CFO, Rule 10b5-1, Stock Vesting, Equity Incentive Plan